Radiopharm Theranostics Limited (RADX)

NASDAQ: RADX · Real-Time Price · USD
7.09
+0.89 (14.35%)
At close: Oct 6, 2025, 4:00 PM EDT
6.95
-0.14 (-1.97%)
After-hours: Oct 6, 2025, 7:37 PM EDT
14.35%
Market Cap51.64M
Revenue (ttm)8.20M
Net Income (ttm)-25.14M
Shares Out 2.36B
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume63,045
Open6.85
Previous Close6.20
Day's Range6.02 - 7.67
52-Week Range3.50 - 50.82
Beta0.80
AnalystsStrong Buy
Price Target15.00 (+111.57%)
Earnings Daten/a

About RADX

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung the... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 14
Stock Exchange NASDAQ
Ticker Symbol RADX
Full Company Profile

Financial Performance

In 2025, Radiopharm Theranostics's revenue was 12.51 million, an increase of 538.86% compared to the previous year's 1.96 million. Losses were -38.34 million, -20.04% less than in 2024.

Financial numbers in AUD Financial Statements

Analyst Summary

According to 3 analysts, the average rating for RADX stock is "Strong Buy." The 12-month stock price target is $15.0, which is an increase of 111.57% from the latest price.

Price Target
$15.0
(111.57% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

There is no news available yet.